This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mandrell, B. N. Articles by Pritchard, M. Search for Related Content PubMed PubMed Citation Articles by Mandrell, B. N. Articles by Pritchard, M. Social Bookmarking                   What's this?

Understanding the Clinical Implications of Minimal Residual Disease in Childhood Leukemia

St. Jude-University of Pennsylvania Distance Learning Program; Department of Nursing Research, Mail Stop 0738, St. Jude Children's Research Hospital, 332 North Lauderdale Street, Memphis, TN 38105-2794 belinda.mandrell{at}stjude.org

Michele Pritchard, MSN, RN, PNP-C

Department of Hematology/Oncology at St. Jude Children's Research Hospital, Memphis, TN.

Improved laboratory techniques now allow a more sensitive detection of leukemia cells at designated intervals throughout therapy. Using flow cytometry and polymerase chain reaction, it is possible to detect 1 leukemic cell among 10 4 normal cells (1 leukemia cell in 10,000 normal cells), representing a 100-fold greater sensitivity than morphological examination in acute lymphoblastic leukemia (ALL). Recently, it has been shown that the molecular presence of persistent acute lymphoblastic leukemia at the end of remission therapy is a poor indicator of clinical outcome. Now similar studies are being performed in acute myeloid leukemia (AML). While the sensitivity using flow cytometry is less in AML than in ALL (able to detect 1 leukemic cell among 1000 normal cells in AML), persistent or minimal residual AML provides the clinician guidance with future treatment recommendations. Minimal residual disease (MRD) is now considered an important indicator response of disease response to treatment. As such, MRD once considered a research variable is now influencing treatment decisions. Therefore, it is imperative that the nurse have an understanding of the newer techniques to study residual leukemia and their clinical implications for patients and their families.

Key Words: minimal residual disease (MRD) • polymerase chain reaction • flow cytomery • cancer • child

Journal of Pediatric Oncology Nursing, Vol. 23, No. 1, 38-44 (2006)
DOI: 10.1177/1043454205284349


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E. Marston, V. Weston, J. Jesson, E. Maina, C. McConville, A. Agathanggelou, A. Skowronska, K. Mapp, K. Sameith, J. E. Powell, et al. Stratification of pediatric ALL by in vitro cellular responses to DNA double-strand breaks provides insight into the molecular mechanisms underlying clinical response Blood, January 1, 2009; 113(1): 117 - 126. [Abstract] [Full Text] [PDF]

				M. Hou, M. Andersson, S. Eksborg, O. Soder, and K. Jahnukainen Xenotransplantation of testicular tissue into nude mice can be used for detecting leukemic cell contamination Hum. Reprod., July 1, 2007; 22(7): 1899 - 1906. [Abstract] [Full Text] [PDF]